Useful links

Please download or view the following resources to
learn more about insomnia, its treatment options,
and DAYVIGO™ (lemborexant)

• Expert opinion on DAYVIGO™ - Coming Soon

• DAYVIGO™ Patient Brochure

• Canadian Sleep & Circadian Network (CSCN)

• Insomnia Academy

INDICATION AND CLINICAL USE:

Sleep disturbance may be the presenting manifestation of a physical and/or psychiatric disorder. Consequently, a
decision to initiate symptomatic treatment of insomnia should only be made after the patient has been carefully
evaluated.

DAYVIGO™ (lemborexant) is indicated for the treatment of insomnia, characterized by difficulties with sleep
onset and/or sleep maintenance.

DAYVIGO™ is not recommended for patients under the age of 18 years.

DAYVIGO™ is not recommended in patients with severe hepatic impairment.

CONTRAINDICATIONS:

• Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or
component of the container.

• Patients with narcolepsy. 

RELEVANT WARNINGS AND PRECAUTIONS:

• Abnormal thinking and behavioural changes 

• CNS depressant effects (including alcohol) and daytime impairment 

• Complex sleep behaviours 

• Sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms 

• Worsening of depression/suicidal ideation 

• Co-morbid diagnoses 

• Drug interactions – inhibitors and inducers of CYP3A 

• Driving and operating machinery 

• Patients with dependence/tolerance and abuse liability 

• Patients with hepatic, biliary, or pancreatic impairment 

• Patients with compromised respiratory function 

• Pregnant or breastfeeding women 

FOR MORE INFORMATION

Please see the Product Monograph for important information on adverse reactions, drug interactions, and dosing
not discussed in this piece.

Sleep disturbance may be the presenting manifestation of a physical and/or psychiatric disorder.
Consequently, a decision to initiate symptomatic treatment of insomnia should only be made after the
patient has been carefully evaluated.

DAYVIGO™ is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or
sleep maintenance.

Click here for additional safety information and for a link to the product monograph, discussing
contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical
use.